Lexicon Pharmaceutical’s Stock Actively Traded After Releasing New Carcinoid Treatment Drug Data (LXRX)

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares saw a dramatic rise in volume after releasing new tumor drug data. On Friday, the company released new information and clinical data about its proposed drug Telotristat. Lexicon is developing Telotristat as a treatment option for a carcinogenic condition created by tumors in the gastrointestinal tract. This carcinoid syndrome affects […]